Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
Described herein are novel compounds and methods for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or solvate thereof.
2. A pharmaceutical composition comprising:
a. the compound of claim 1 ; and
b. at least one pharmaceutically acceptable carrier.
3. A method for treating Alzheimer's disease and/or cerebral amyloid angiopathy in a patient diagnosed with the same, the method comprising administering to the patient an effective amount of the compound of claim 1 .
4. The method of claim 3 , wherein the administration of an effective amount of the compound increases processing of one or more gangliosides selected from GM2 and GA2.
5. A method for enhancing the activity of β-hexosaminidase, the method comprising administering an effective amount of the compound of claim 1 .
6. A kit comprising:
a. the compound of claim 1 ; and
b. instructing for using the same to treat Alzheimer's disease and/or cerebral amyloid angiopathy.
7. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
8. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
9. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
10. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
11. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
12. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.
13. The compound of claim 1 , wherein the compound comprises:
or a pharmaceutically acceptable salt or solvate thereof.